Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment of AVPC (aggressive variant prostate cancer) and NEPC (neuroendocrine prostate cancer).

NCT Number	NCT07179783
Lead Sponsor	Tianjin Medical University Second Hospital Collaborators: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions	Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
Enrollment	28 participants
Start Date	2025-09-22
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-07-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-18